Amphastar Pharmaceuticals, Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Mar 2017 | $110.1M | $435.6M | $76.8M |
| Jun 2017 | $110.7M | $444.0M | $82.5M |
| Sep 2017 | $107.1M | $437.8M | $66.9M |
| Dec 2017 | $117.3M | $451.1M | $65.6M |
| Mar 2018 | $122.7M | $449.8M | $54.5M |
| Jun 2018 | $131.1M | $451.6M | $48.1M |
| Sep 2018 | $139.4M | $480.6M | $68.7M |
| Dec 2018 | $149.2M | $513.6M | $86.3M |
| Mar 2019 | $164.5M | $544.7M | $79.1M |
| Jun 2019 | $169.0M | $601.3M | $120.4M |
| Sep 2019 | $152.0M | $585.6M | $85.6M |
| Dec 2019 | $159.4M | $587.0M | $73.7M |
| Mar 2020 | $149.5M | $572.8M | $54.8M |
| Jun 2020 | $157.6M | $600.1M | $87.4M |
| Sep 2020 | $162.8M | $613.7M | $87.9M |
| Dec 2020 | $182.5M | $631.2M | $92.6M |
| Mar 2021 | $194.8M | $645.7M | $101.6M |
| Jun 2021 | $198.5M | $665.7M | $105.4M |
| Sep 2021 | $221.5M | $651.7M | $106.6M |
| Dec 2021 | $226.0M | $671.5M | $126.4M |
| Mar 2022 | $236.7M | $716.2M | $172.6M |
| Jun 2022 | $224.4M | $723.7M | $166.2M |
| Sep 2022 | $221.5M | $726.7M | $157.2M |
| Dec 2022 | $213.3M | $742.0M | $156.1M |
| Mar 2023 | $225.1M | $773.7M | $176.6M |
| Jun 2023 | $789.0M | $1.38B | $148.6M |
| Sep 2023 | $949.5M | $1.54B | $266.8M |
| Dec 2023 | $873.5M | $1.51B | $144.3M |
| Mar 2024 | $902.0M | $1.57B | $201.1M |
| Jun 2024 | $778.2M | $1.49B | $189.6M |
| Sep 2024 | $817.5M | $1.55B | $192.1M |
| Dec 2024 | $845.2M | $1.58B | $151.6M |
| Mar 2025 | $875.0M | $1.63B | $182.8M |
| Jun 2025 | $857.9M | $1.62B | $187.7M |
| Sep 2025 | $889.5M | $1.67B | $216.3M |
| Dec 2025 | $840.5M | $1.63B | $170.2M |
| Mar 2026 | $874.8M | $1.65B | $170.9M |
| Jun 2026 | $975.6M | $1.74B | $223.6M |